Nk1-antagonist combination and method for treating synucleinopathies

Abstract

The present invention describes the use of a NK1-antagonist, in combination with 6- propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from asynucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone.

Description

[0001] related application

[0002] This application claims the benefit of US Provisional Patent Application Serial No. 62 / 483,555, filed April 10, 2017, the disclosure of which is hereby incorporated by reference in its entirety. technical field

[0003] The present invention relates to the field of treatment of synucleinopathies, ie neurodegenerative diseases of the human central nervous system, and in particular to the treatment of neurotoxic processes due to oligomerization and aggregation of alpha-synuclein.

[0004] Purpose of the invention

[0005] The present invention relates to pharmaceutical combinations (including fixed dose combinations) comprising 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine or a pharmaceutically acceptable salt thereof or solvates and neurokinin receptor subtype 1 antagonists ("NK1-antagonists"), and their use for the treatment of synucleinopathies, in particular for the treatment of blood plasma exosomes / total α-co- CNS neurot...

Images